Literature DB >> 22986744

OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Ren-Yuan Bai1, Verena Staedtke, Hart G Lidov, Charles G Eberhart, Gregory J Riggins.   

Abstract

The brain development transcription factor OTX2 is overexpressed and/or genomically amplified in most medulloblastomas, but the mechanistic basis for its contributions in this setting are not understood. In this study, we identified OTX2 as a transcriptional repressor and a gatekeeper of myogenic and neuronal differentiation in medulloblastoma cells. OTX2 binds to the MyoD1 core enhancer through its homeobox domain, and the remarkable repressor activity exhibited by the homeobox domain renders OTX2 transcriptionally repressive. RNA interference-mediated attenuation of OTX2 expression triggered myogenic and neuronal differentiation in vitro and prolonged the survival in an orthotopic medulloblastoma mouse model. Conversely, inducing myogenic conversion of medulloblastoma cells led to the loss of OTX2 expression. In medullomyoblastoma, a medulloblastoma subtype containing muscle elements, myogenic cells share cytogenetic signatures with the primitive tumor cells and OTX2 expression was lost in the differentiated myogenic cells. Thus, OTX2 functions via its homeobox domain as a suppressor of differentiation, and the loss of OTX2 expression is linked to the myogenesis in medullomyoblastoma. Together, our findings illustrate the origin of muscle cells in medullomyoblastomas and the oncogenic mechanism of OTX2 as a repressor of diverse differentiating potential. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22986744      PMCID: PMC4861240          DOI: 10.1158/0008-5472.CAN-12-0614

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Gbx2 and Otx2 interact with the WD40 domain of Groucho/Tle corepressors.

Authors:  Thomas Heimbucher; Christina Murko; Baubak Bajoghli; Narges Aghaallaei; Anja Huber; Ronald Stebegg; Dirk Eberhard; Maria Fink; Antonio Simeone; Thomas Czerny
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

2.  Medullomyoblastoma: a histological, immunohistochemical, ultrastructural and molecular genetic study.

Authors:  M Bergmann; T Pietsch; J Herms; J Janus; H J Spaar; B Terwey
Journal:  Acta Neuropathol       Date:  1998-02       Impact factor: 17.088

3.  Molecular dissection reveals decreased activity and not dominant negative effect in human OTX2 mutants.

Authors:  Gilles Chatelain; Nicolas Fossat; Gilbert Brun; Thomas Lamonerie
Journal:  J Mol Med (Berl)       Date:  2006-04-11       Impact factor: 4.599

4.  Expression of the Otx2 homeobox gene in the developing mammalian brain: embryonic and adult expression in the pineal gland.

Authors:  Martin F Rath; Estela Muñoz; Surajit Ganguly; Fabrice Morin; Qiong Shi; David C Klein; Morten Møller
Journal:  J Neurochem       Date:  2006-03-15       Impact factor: 5.372

5.  Meis2 competes with the Groucho co-repressor Tle4 for binding to Otx2 and specifies tectal fate without induction of a secondary midbrain-hindbrain boundary organizer.

Authors:  Zsuzsa Agoston; Dorothea Schulte
Journal:  Development       Date:  2009-10       Impact factor: 6.868

6.  OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.

Authors:  Talitha de Haas; Esmeralda Oussoren; Wieslawa Grajkowska; Marta Perek-Polnik; Mara Popovic; Lorna Zadravec-Zaletel; Marzia Perera; Giorgio Corte; Oliver Wirths; Peter van Sluis; Torsten Pietsch; Dirk Troost; Frank Baas; Rogier Versteeg; Marcel Kool
Journal:  J Neuropathol Exp Neurol       Date:  2006-02       Impact factor: 3.685

7.  Cloning and characterization of a novel MyoD enhancer-binding factor.

Authors:  Masakazu Yamamoto; Christopher D Watt; Ryan J Schmidt; Unsal Kuscuoglu; Roger L Miesfeld; David J Goldhamer
Journal:  Mech Dev       Date:  2007-07-10       Impact factor: 1.882

8.  Identification of potential target genes for the neuron-restrictive silencer factor.

Authors:  C J Schoenherr; A J Paquette; D J Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Otx2 controls identity and fate of glutamatergic progenitors of the thalamus by repressing GABAergic differentiation.

Authors:  Eduardo Puelles; Dario Acampora; Robindra Gogoi; Francesca Tuorto; Alessandro Papalia; Francois Guillemot; Siew-Lan Ang; Antonio Simeone
Journal:  J Neurosci       Date:  2006-05-31       Impact factor: 6.167

10.  Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.

Authors:  Matthew Wortham; Genglin Jin; Julia Lailai Sun; Darell D Bigner; Yiping He; Hai Yan
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

View more
  23 in total

Review 1.  Genetic and molecular alterations across medulloblastoma subgroups.

Authors:  Patryk Skowron; Vijay Ramaswamy; Michael D Taylor
Journal:  J Mol Med (Berl)       Date:  2015-09-09       Impact factor: 4.599

Review 2.  OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma.

Authors:  Yining Lu; Collin M Labak; Neha Jain; Ian J Purvis; Maheedhara R Guda; Sarah E Bach; Andrew J Tsung; Swapna Asuthkar; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

3.  Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.

Authors:  Ren-Yuan Bai; Verena Staedtke; Charles M Rudin; Fred Bunz; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

4.  OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.

Authors:  Gaylor Boulay; Mary E Awad; Nicolo Riggi; Tenley C Archer; Sowmya Iyer; Wannaporn E Boonseng; Nikki E Rossetti; Beverly Naigles; Shruthi Rengarajan; Angela Volorio; James C Kim; Jill P Mesirov; Pablo Tamayo; Scott L Pomeroy; Martin J Aryee; Miguel N Rivera
Journal:  Cancer Discov       Date:  2017-02-17       Impact factor: 39.397

5.  MiR-206, a Cerebellum Enriched miRNA Is Downregulated in All Medulloblastoma Subgroups and Its Overexpression Is Necessary for Growth Inhibition of Medulloblastoma Cells.

Authors:  Pooja Panwalkar; Aliasgar Moiyadi; Atul Goel; Prakash Shetty; Naina Goel; Epari Sridhar; Neelam Shirsat
Journal:  J Mol Neurosci       Date:  2015-04-10       Impact factor: 3.444

6.  Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.

Authors:  Ren-Yuan Bai; Verena Staedtke; Teresia Wanjiku; Michelle A Rudek; Avadhut Joshi; Gary L Gallia; Gregory J Riggins
Journal:  Clin Cancer Res       Date:  2015-04-10       Impact factor: 12.531

7.  Impact of Reck expression and promoter activity in neuronal in vitro differentiation.

Authors:  Marina Trombetta-Lima; Thais Assis-Ribas; Ricardo C Cintra; Joana D Campeiro; Juliano R Guerreiro; Sheila M B Winnischofer; Isis C C Nascimento; Henning Ulrich; Mirian A F Hayashi; Mari C Sogayar
Journal:  Mol Biol Rep       Date:  2021-02-22       Impact factor: 2.316

8.  MyoD is a tumor suppressor gene in medulloblastoma.

Authors:  Joyoti Dey; Adrian M Dubuc; Kyle D Pedro; Derek Thirstrup; Brig Mecham; Paul A Northcott; Xiaochong Wu; David Shih; Stephen J Tapscott; Michael LeBlanc; Michael D Taylor; James M Olson
Journal:  Cancer Res       Date:  2013-10-03       Impact factor: 12.701

Review 9.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

10.  The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.

Authors:  Carolina Nör; Felipe A Sassi; Caroline Brunetto de Farias; Gilberto Schwartsmann; Ana Lucia Abujamra; Guido Lenz; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2013-03-21       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.